ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release its views regarding the opportunity and implications of recent advancements in the area of Alzheimer's treatment.
ProMIS Neurosciences indicated that in January 2021, two important events transpired that it believes are quite positive for the Alzheimer's field, the updated amyloid hypothesis and for the company as well.
The first event occurred when Eli Lilly and Co. (LLY:NYSE) reported positive clinical results for its antibody donanemab on January 11, 2021. Eli Lilly's donanemab is the third therapeutic antibody that demonstrated positive clinical results in Alzheimer's disease that was designed to specifically target aggregated amyloid-beta (not amyloid monomer). Lilly's TRAILBLAZER trial included 272 subjects who were given donanemab, which targets pyroglutamated amyloid-beta that is known to be involved in toxic oligomer formation.
The second event was when the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee (PDUFA) date for review of Biogen Inc.'s (BIIB:NASDAQ) aducanumab to June 7, 2021, from March 7, 2021.
The date was pushed back by the FDA due to a negative non-binding advisory committee vote. Nonetheless, ProMIS feels that this is just a temporary setback and that it appears that the FDA review division strongly believes that the high dose of 10mg/kg aducanumab is clinically beneficial and warrants approval and that it expects that the FDA will grant approval for aducanumab in the summer of 2021.
ProMIS stated that each of these events offers very positive implications for the company and PMN310, its leading antibody therapeutic candidate for treating Alzheimer's disease developed to be highly selective for toxic oligomers. The company noted that there are now three programs showing clinical benefit due to the targeting of aggregated amyloid, which will likely impact toxic oligomers. The firm stated that the new collective clinical evidence serves to update the amyloid hypothesis supporting the view that ProMIS' PMN310 can be dosed higher and will likely avoid the ARIA-E side effect thus offering "best in class efficacy."
ProMIS Neurosciences' Executive Chairman Eugene Williams remarked, "Several analysts predicted that the FDA might manage its dilemma of believing that aducanumab should be approved despite a negative advisory committee vote by waiting for data to come in from the ongoing high dose extension study, extending the PDUFA date, and then approving the product later. It appears that prediction was correct...In line with this assessment, we believe the FDA will issue an approval of aducanumab in the summer of 2021."
ProMIS stated that it uses its unique core technology "to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins," and that in ALS, Alzheimer's and Parkinson's diseases, the DSEs are misfolded regions on toxic forms of otherwise normal proteins.
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
